Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EML4 - NTRK3||Advanced Solid Tumor||predicted - sensitive||Entrectinib||Case Reports/Case Series||Actionable||In a Phase Ib/II trial (STARTRK-NG), a patient with an advanced solid tumor harboring EML4-NTRK3 demonstrated a partial response when treated with Rozlytrek (entrectinib) (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 107-107; NCT02650401).||detail...|
|EML4 - NTRK3||Advanced Solid Tumor||predicted - sensitive||Entrectinib||Preclinical - Cell culture||Actionable||In a preclinical study, Rozlytrek (entrectinib) inhibited growth of transformed cells expressing EML4-NTRK3 in culture (PMID: 30279230).||30279230|
|PubMed Id||Reference Title||Details|
|(30279230)||Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability-High Colorectal Cancers.||Full reference...|
|Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.||Full reference...|